Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNF2007 in Advanced Solid Tumors
NCT06752447Phase 1Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of LNF-2007 in solid tumor (advanced stage), sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Incidence of LNF2007 treatment-emergent adverse events, Occurrence of dose-limiting toxicity at 28 days and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
LNF-2007
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06752447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752447.